Exchange: NASDAQ·Updated 03:40 PM EDT

NTLA News

News
all
press releases
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
More News
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Stocktwits
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Stocktwits
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Zacks
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Zacks
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Zacks
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.
Stocktwits
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Zacks
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.